Clinical trials: Hematological Patients
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART C (NCT05745714)
- Testing
- Ruxolitinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Trial name
- HEM-iSMART E (NCT07175415)
- Testing
- Capivasertib, Venetoclax, Dexamethasone
- Volunteers
- 42 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Hematological Malignancy, Neoplasm Metastasis
Treatment of Patients With Donor Lymphocytes Sensitized by Antigens Expressed by the Host
Allogeneic stem cell transplantation is the only effective treatment to patients resistant to conventional chemotherapy. Donor lymphocytes infusion (DLI) serve as a routine treatment of choice for patients relapsing following…
- Trial name
- NCT00149032
- Testing
- DLI sensitized against antigens expressed by the host.
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Solid Tumor, Sars-CoV2
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
This study is for patients that are hospitalized for Coronavirus Disease 2019 (COVID-19). The purpose of this study is to see whether neutralizing interleukin-8 (IL-8) with BMS-986253 can help improve the health condition of…
- Conditions
- Solid Tumor, Sars-CoV2, Hematological Malignancy
- Trial name
- NCT04347226
- Testing
- BMS-986253
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Columbia University
AML, ALL
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
This is a multicenter, open-label, dose escalation Phase 1 study.
- Conditions
- AML, ALL, Blast Crisis, MDS
- Trial name
- TG02-101 (NCT01204164)
- Testing
- TG02 citrate, Carfilzomib, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
RSV Infection
An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute)
This primary objective of this study is to describe the incidence of RSV infection in adult hematopoietic cell transplant recipients OR hematological malignancies patients in Tianjin HI.
- Trial name
- NCT06490549
- Testing
- RSV infection observation cohort
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Unspecified Adult Solid Tumor, Protocol Specific
Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00009828
- Testing
- leucovorin calcium, paclitaxel, tegafur-uracil
- Sponsor
- University of Pittsburgh
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Hematological Malignancies
The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"
The purpose of this study is to determine: Condition of intensive care unit (ICU) admission in patients with haematological malignancies. ICU hospital and up to one year mortality.
- Trial name
- NCT01172132
- Where
- France
- Volunteers
- 1,011 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiovascular Risk Factors, Fasting
Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors
Ramadan Fasting has multiple effects on the variation of hematological and biochemical parameters.
- Trial name
- NCT02720133
- Testing
- biochemical parameters
- Where
- Tunisia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Monastir
Hematological Malignancies
Compassionate Use Study of Tenalisib (RP6530)
Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these…
- Trial name
- NCT03711604
- Testing
- Tenalisib
- Where
- 7 sites in United States, Georgia and 1 more
- Volunteers
- 17 people
- Sponsor
- Rhizen Pharmaceuticals SA
Graft Versus Host Disease
Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
The purpose of this study is to analyze the results of incidence and severity of acute and chronic GVHD, (see addendum II) and of disease free survival with Alemtuzumab use (MabCampath®) in haematopoietic transplant of unrelated…
- Trial name
- NCT00781781
- Testing
- Alemtuzumab
- Where
- 10 sites in Spain
- Volunteers
- 34 people
- Sponsor
- CABYC
Relapsed/Refractory Solid Tumors/Hematological Malignancies
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
A phase I, open-label, nonrandomized study to determine the PK profile of belinostat in patients with relapsed/refractory solid tumors or hematological malignancies in patients with renal impairment.
- Trial name
- NCT02679131
- Testing
- Belinostat
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Acrotech Biopharma Inc.
Hematological Diseases
Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation
Haemopoietic stem cell transplantation (HSCT) has become a major life-saving treatment for many haematological conditions, mostly malignancies.
- Trial name
- NCT00956358
- Where
- Hong Kong
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
The purpose of this study is to see if exercise fitness testing is feasible and safe in persons over 21 years of age who have been diagnosed with a hematological malignancy and are scheduled to undergo a hematopoietic stem cell…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Hematological Malignancy, Leukemia
- Trial name
- NCT02598752
- Testing
- Symptom-limited cardiopulmonary exercise test (CPET), Resting assessment of cardiac function by echocardiography, Post-exercise assessment of cardiac function by echocardiography
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematological Cancer
Progressive Relaxation and Psychoeducation in Patients With Hematological Malignancies
This study will be conducted to determine the effect of progressive relaxation and psychoeducation on perceived stress and hope in patients with hematological malignancies
- Trial name
- NCT07251348
- Testing
- Muscle Relaxation, psychoeducation or Atomoxetine or stimulants according to ADHD severity
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Necmettin Erbakan University
Poorly Controlled Diabetes Mellitus
Changes in Hematological Parameters With Glycemia Control in Type 2 Diabetes
There is a systemic low-grade chronic inflammation in diabetes, and research suggests that this inflammation plays a vital role in the development of diabetic complications.
- Trial name
- NCT06228898
- Where
- Turkey (Türkiye)
- Volunteers
- 170 people
- Sponsor
- Goztepe Prof Dr Suleyman Yalcın City Hospital
Acute Myeloid Leukemia
MRD-guided Treatment in NPM1mut AML Patients
Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable…
- Trial name
- PEMAZA (NCT03769532)
- Testing
- Pembrolizumab, Azacitidine
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
Single patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.
- Trial name
- NCT05593185
- Testing
- Galinpepimut-S
- Sponsor
- Sellas Life Sciences Group
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc